Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cizutamig in IgA Nephropathy
NCT07135219Phase 1Enrolling by invitation
- Sponsor
- Peking University First Hospital
- Start
- Jul 2025
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cizutamig in immunoglobulin A nephropathy (IgAN), sponsored by Peking University First Hospital. Primary endpoint: Number of participants with treatment-related adverse events at 52 weeks. Started Jul 2025; status: enrolling by invitation.
02
Drugs
cizutamig
03
Conditions
immunoglobulin A nephropathy (IgAN)
Beyond the preview
Go deeper on NCT07135219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07135219.